Any CancerPROACTNCT06479057
PROACT is a Prospective Master Protocol for a Cohort Study Focused on Evaluating the Implementation of Integrated Proactive Supportive Care Pathways at Gustave Roussy
An observational study of Any Cancer, run by Gustave Roussy, Cancer Campus, Grand Paris at 1 site in France.
Trial summary
PROACT is a prospective master protocol for a cohort study focused on evaluating the implementation of integrated proactive pathways of supportive care. This is an observational cohort study in the context of a quality-of-care initiative. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Any Cancer
- What is being tested?
- Supportive Care Pathway
- How many people
- 700 participants
- Where
- 1 siteFrance
- Study dates
- 11 Jan 2024to Jul 2027
- How long will I take part?
- 6 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patient with any cancer type, any stage receiving supportive care interventions at Gustave Roussy. For the primary endpoint all the patients participating in supportive care pathways with formal supportive care needs assessment and targeted referrals will be invited to participate. For the secondary endpoints, any patient included in the supportive care interventions at the institution may participate.
Who may be able to join
- Histological confirmation of cancer (any cancer type, any stage)
- Age ≥ 18 years old
- Received an integrated supportive care need assessment.
- Sign the consent form for the PROACT study.
Who cannot join
- Absence or inability of written consent from the patient.
- Does not understand or speak French.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Maria Alice BORINELLI-FRANZOI contact
France1 site, 1 recruiting
- Recruiting
Gustave Roussy
Villejuif, 94800
Ines VAZ LUIS, INES-MARIA.VAZ-DUARTE-LUIS@gustaveroussy.fr
Aude BARBIER, aude.barbier@gustaveroussy.fr
About this study
Official title: Integrating PROACTive Care Pathways to Empower and Support Cancer Patients (PROACT)
PROACT is a prospective master protocol for a cohort study focused on evaluating the implementation of integrated proactive pathways of supportive care.
This is an observational cohort study in the context of a quality-of-care initiative.
It will be evaluated by its impact on patient's distress measured by the NCCN's Distress thermometer at 12 weeks after entering the pathway.
Read the detailed description
The primary study endpoint of PROACT is patient distress and supportive care needs (NCCN Distress Thermometer and NCCN Problem list) over a 12-week period after the supportive care needs assessment and referrals in the context of a PROACT pathway.
Secondary study endpoints include:
- To evaluate the Reach of each pathway through the number of patients who participated in supportive care needs' assessment and in each supportive care intervention (administrative review of attendance log)
- To evaluate the diversity of patients included in each pathways through evaluation of sociodemographic and economic profile (Socioeconomic and demographic self-reported questionnaire)
- To evaluate the impact of each pathway and each supportive care intervention on patient's overall health status (EQ-E5-EL)
- To evaluate the impact of each pathway and each supportive care intervention on patient's quality of life (EORTC QLQ C30)
- To evaluate the impact of each pathway and each supportive care intervention on symptom burden (MDASI)
- To evaluate the impact of each pathway and each supportive care intervention on anxiety (HADS)
- To evaluate the impact of each pathway and each supportive care intervention on Insomnia levels (ISI)
- To evaluate the impact of each pathway and each supportive care intervention on sexual health (EORTC SHQ-C22)
- To evaluate the Physician's Adoption of each pathway through the proportion of physicians referring patients to the pathways (referral log)
- To evaluate patient's adoption through the proportion of patients adhering to supportive care interventions as intended (attendance log)
- To evaluate patient experience and satisfaction with the pathways (PACIC and adhoc satisfaction questionnaires.
- To evaluate implementation in through a qualitative analyses of experience, implementation barriers and facilitators (focus groups with patients and providers)
- To plan for Maintenance of the pathway through a cost effectiveness analysis.
- To evaluate the impact of each pathway and each supportive care intervention on Intestinal Symptoms (LARS score). if indicated for the specific population
- To evaluate the impact of each pathway and each supportive care intervention on Anal Incontinence (Wexner score). if indicated for the specific population
- To evaluate the impact of each pathway and each supportive care intervention on Urinary Symptoms (USP score). if indicated for the specific population
- To evaluate the impact of each pathway and each supportive care intervention on Hematologic Cancer (FACT-BMT)
- To evaluate the impact of each pathway and each supportive care intervention on Montgomery Borgatta Caregiver Burden Scale. if indicated for the specific population.
- To evaluate the healthcare professionals participating in the pathway to screen vulnerability and prevent treatment related burden (F-SUS)
This is a master protocol study that is conducted by collecting sub-studies for each supportive care intervention which share key design components and operational aspects leading to a higher level of coordination than the one achieved by independently conducted studies.
Methodology: it is a mix of quantitative and qualitative methods to assess the Reach, Efficacy and potential for Adoption, while identifying barriers to Implementation and strategies to Maintain the pathway in the institution guided by the RE-AIM framework. Data collection will allow evaluation in a macro level (integrated supportive care pathway including supportive care needs assessment and tailored multidisciplinary referrals) and in a micro level (separated for each supportive care intervention).
- Conditions
- Any Cancer
- Being tested
- Supportive Care Pathway
- Keywords
- supportive care pathway, cancer, master protocol, supportive care, Distress
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Supportive Care PathwayOther
All pathways include a medical consultation with comprehensive needs assesment and evidence-based coordinated supportive care referrals at institutional and community-based level.
| Study group | Role | What they receive |
|---|---|---|
| PROACT Supportive Care pathways | This is a prospective cohort study including patients participating in institutional supportive care pathways at diagnosis, during treatment and after treatment. Receives: Other: Supportive Care Pathway |
What is being measured
The primary outcome is the main question the study is designed to answer.
Patient distress
Patient distress collected with NCCN Distress Thermometer
Measured: over a 12-week period after the integrated supportive care needs assessment.
Patient unmet needs
Patient unmet needs collected with problem list from NCCN Distress thermometer
Measured: over a 12-week period after the integrated supportive care needs assessment.
Secondary outcomes (21)
Reach of the pathway
Proportion of patients who accepted the supportive care needs assessment (descriptive numbers from attendance log)
Measured: week 12
Diversity of pathway participants
Socioeconomic characteristics of participants in the pathway measure by a self-reported socioeconomic questionnaire
Measured: week 12
Impact of the pathway in overall health status
Overall health status measured by the EQ-ED-5L
Measured: week 12, and 24
Impact of the pathway in Quality of life
Quality of life measured by the EORTC QLQ C30
Measured: week 12, and 24
Impact of the pathway in symptom burden
Symptom burden measured by the MDASI Questionnaire.
Measured: week 12, and 24
Impact of the pathway on anxiety levels
Anxiety measured by HADS
- only for patients reporting anxiety at baseline
Measured: week 12, and 24
Impact of the pathway on insomnia levels
Insomnia measured by ISI
*only for patients reporting insomnia at baseline
Measured: week 12, and 24
Impact of the pathway on sexual health
Sexual health measured by EORTC SHQ-C22
*only for patients reporting sexual dysfunction at baseline
Measured: week 12, and 24
Adoption of Physician
Proportion of physicians referring patients to the supportive care pathway (descriptive numbers from referral logs)
Measured: week 12
Adoption of Patient
Proportion and of patients that fully adopted each supportive care intervention (e.g.; in the after cancer pathway: attendance to consultations/seminaries/classes, completion of a supportive care program, usage data for Resilience app).
Measured: week 12
Patient Experience
Patient experience measured by the PACIC questionnaire.
Measured: week 12
Patient Satisfaction with the pathway
Patient satisfaction measured by an ad hoc satisfaction questionnaire
Measured: week 12
Provider Experience - Qualitative evaluation
Focus groups with healthcare providers to explore overall experience, workload and implementation challenges
Measured: week 12
Patient Satisfaction/Experience - Qualitative evaluation
Focus groups with patient to explore overall experience and implementation challenges
Measured: week 12
Maintenance of the pathway through a cost effectiveness analysis (QALYs)
Maintenance of the pathway through a cost effectiveness analysis. Costs from the perspective of the French national health insurance will be assessed during the study period. This will be calculated by administrative data review of internal allocated resources for pathway delivery and estimated costs of use of hospital services (unplanned hospitalization, consultations, and emergency visits recorded in the electronic medical records).
QALYs (quality-adjusted life years) will be measured using utility values derived from the EuroQol-5D (EQ-5D-5L) (https://euroqol.org/) for French general population (Andrade et al. PharmacoEconomics 2020). QALYs will be computed combining survival time by utility values.
Measured: week 12
Impact of the pathway on Intestinal Symptom
Intestinal Symptoms measured by LARS score.
*only for patients with digestive cancer
Measured: week 24
Impact of the pathway on Anal incontinence
Anal incontinence measured by Wexner score.
*only for patients with digestive cancer
Measured: week 24
Impact of the pathway on Urinary symptoms
Urinary symptoms measured by USP score.
*only for patients with digestive cancer
Measured: week 24
Impact of the pathway on Functional Assessment of Cancer Therapy-Bone Marrow Transplant
Functional Assessment of Cancer Therapy-Bone Marrow Transplant measured by FACT-BMT score.
*only for patients with Hematologic Cancer
Measured: week 12, week 24
Impact of the pathway on caregiver burden
Caregiver burden measured by Montgomery Borgatta Caregiver Burden Scale.
Measured: week 12
Impact of the pathway on healthcare professionals participating in the pathway to screen vulnerability and prevent treatment
Healthcare professionals measured by F-SUS Score
Measured: week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jun 2024
- Study start11 Jan 2024
- Primary completionJan 2027 (estimated)
- Study completionJul 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Any CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 700 participants (estimated)
- Target duration
- 6 Months
Sponsor and investigators
- Lead sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Ines VAZ LUIS, Principal investigator, Gustave Roussy, Cancer Campus, Grand Paris
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06479057
- Sponsor's protocol ID
- 2023-A01225-40
- Other IDs
- 2023/3662
- Acronym
- PROACT
- Status last verified
- Jan 2026
- First submitted
- 5 Apr 2024
- Last updated
- 16 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Franzoi MA, Santolaya C, Martin E, Fasse L, Rouby P, Minot-This MS, Di Meglio A, Vaz-Luis I. "Let's talk about risk": co-designing a pathway to assess, communicate and act on individual risk of long-term toxicities after breast cancer. J Cancer Surviv. 2025 Jun 12. doi: 10.1007/s11764-025-01826-0. Online ahead of print.
PubMed 40504480Franzoi MA, Pages A, Papageorgiou L, Di Meglio A, Laparra A, Martin E, Barbier A, Renvoise N, Arvis J, Scotte F, Vaz-Luis I. Evaluating the Implementation of Integrated Proactive Supportive Care Pathways in Oncology: Master Protocol for a Cohort Study. JMIR Res Protoc. 2024 Aug 26;13:e52841. doi: 10.2196/52841.
PubMed 39186774
Study at a glance
From the registry record, last updated by the sponsor on 16 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Integrating PROACTive Care Pathways to Empower and Support Cancer Patients (PROACT)
- ClinicalTrials.gov ID
- NCT06479057
- Acronym / sponsor ID
- PROACT / 2023-A01225-40
- Conditions
- Any Cancer
- Keywords
- supportive care pathway, cancer, master protocol, supportive care, Distress
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 700 participants (estimated)
- Lead sponsor
- Gustave Roussy, Cancer Campus, Grand ParisUniversity, hospital or other
- Study start
- 11 Jan 2024 (actual)
- Primary completion
- Jan 2027 (estimated)
- Study completion
- Jul 2027 (estimated)
- First posted
- 27 Jun 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
PROACT is a prospective master protocol for a cohort study focused on evaluating the implementation of integrated proactive pathways of supportive care.
This is an observational cohort study in the context of a quality-of-care initiative.
It will be evaluated by its impact on patient's distress measured by the NCCN's Distress thermometer at 12 weeks after entering the pathway.
Detailed description
The primary study endpoint of PROACT is patient distress and supportive care needs (NCCN Distress Thermometer and NCCN Problem list) over a 12-week period after the supportive care needs assessment and referrals in the context of a PROACT pathway.
Secondary study endpoints include:
- To evaluate the Reach of each pathway through the number of patients who participated in supportive care needs' assessment and in each supportive care intervention (administrative review of attendance log)
- To evaluate the diversity of patients included in each pathways through evaluation of sociodemographic and economic profile (Socioeconomic and demographic self-reported questionnaire)
- To evaluate the impact of each pathway and each supportive care intervention on patient's overall health status (EQ-E5-EL)
- To evaluate the impact of each pathway and each supportive care intervention on patient's quality of life (EORTC QLQ C30)
- To evaluate the impact of each pathway and each supportive care intervention on symptom burden (MDASI)
- To evaluate the impact of each pathway and each supportive care intervention on anxiety (HADS)
- To evaluate the impact of each pathway and each supportive care intervention on Insomnia levels (ISI)
- To evaluate the impact of each pathway and each supportive care intervention on sexual health (EORTC SHQ-C22)
- To evaluate the Physician's Adoption of each pathway through the proportion of physicians referring patients to the pathways (referral log)
- To evaluate patient's adoption through the proportion of patients adhering to supportive care interventions as intended (attendance log)
- To evaluate patient experience and satisfaction with the pathways (PACIC and adhoc satisfaction questionnaires.
- To evaluate implementation in through a qualitative analyses of experience, implementation barriers and facilitators (focus groups with patients and providers)
- To plan for Maintenance of the pathway through a cost effectiveness analysis.
- To evaluate the impact of each pathway and each supportive care intervention on Intestinal Symptoms (LARS score). if indicated for the specific population
- To evaluate the impact of each pathway and each supportive care intervention on Anal Incontinence (Wexner score). if indicated for the specific population
- To evaluate the impact of each pathway and each supportive care intervention on Urinary Symptoms (USP score). if indicated for the specific population
- To evaluate the impact of each pathway and each supportive care intervention on Hematologic Cancer (FACT-BMT)
- To evaluate the impact of each pathway and each supportive care intervention on Montgomery Borgatta Caregiver Burden Scale. if indicated for the specific population.
- To evaluate the healthcare professionals participating in the pathway to screen vulnerability and prevent treatment related burden (F-SUS)
This is a master protocol study that is conducted by collecting sub-studies for each supportive care intervention which share key design components and operational aspects leading to a higher level of coordination than the one achieved by independently conducted studies.
Methodology: it is a mix of quantitative and qualitative methods to assess the Reach, Efficacy and potential for Adoption, while identifying barriers to Implementation and strategies to Maintain the pathway in the institution guided by the RE-AIM framework. Data collection will allow evaluation in a macro level (integrated supportive care pathway including supportive care needs assessment and tailored multidisciplinary referrals) and in a micro level (separated for each supportive care intervention).
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Target follow-up
- 6 Months
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| PROACT Supportive Care pathways | – | Other: Supportive Care PathwayThis is a prospective cohort study including patients participating in institutional supportive care pathways at diagnosis, during treatment and after treatment. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patient with any cancer type, any stage receiving supportive care interventions at Gustave Roussy. For the primary endpoint all the patients participating in supportive care pathways with formal supportive care needs assessment and targeted referrals will be invited to participate. For the secondary endpoints, any patient included in the supportive care interventions at the institution may participate.
Key inclusion criteria (4 listed)
- Histological confirmation of cancer (any cancer type, any stage)
- Age ≥ 18 years old
- Received an integrated supportive care need assessment.
- Sign the consent form for the PROACT study.
Key exclusion criteria (2 listed)
- Absence or inability of written consent from the patient.
- Does not understand or speak French.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Supportive Care PathwayAll pathways include a medical consultation with comprehensive needs assesment and evidence-based coordinated supportive care referrals at institutional and community-based level. | Other | PROACT Supportive Care pathways |
Primary outcome
Patient distress
Time frame: over a 12-week period after the integrated supportive care needs assessment.
Patient distress collected with NCCN Distress Thermometer
Patient unmet needs
Time frame: over a 12-week period after the integrated supportive care needs assessment.
Patient unmet needs collected with problem list from NCCN Distress thermometer
21 secondary outcomes
Reach of the pathway
Time frame: week 12
Diversity of pathway participants
Time frame: week 12
Impact of the pathway in overall health status
Time frame: week 12, and 24
Impact of the pathway in Quality of life
Time frame: week 12, and 24
Impact of the pathway in symptom burden
Time frame: week 12, and 24
Impact of the pathway on anxiety levels
Time frame: week 12, and 24
Impact of the pathway on insomnia levels
Time frame: week 12, and 24
Impact of the pathway on sexual health
Time frame: week 12, and 24
Adoption of Physician
Time frame: week 12
Adoption of Patient
Time frame: week 12
Patient Experience
Time frame: week 12
Patient Satisfaction with the pathway
Time frame: week 12
Provider Experience - Qualitative evaluation
Time frame: week 12
Patient Satisfaction/Experience - Qualitative evaluation
Time frame: week 12
Maintenance of the pathway through a cost effectiveness analysis (QALYs)
Time frame: week 12
Impact of the pathway on Intestinal Symptom
Time frame: week 24
Impact of the pathway on Anal incontinence
Time frame: week 24
Impact of the pathway on Urinary symptoms
Time frame: week 24
Impact of the pathway on Functional Assessment of Cancer Therapy-Bone Marrow Transplant
Time frame: week 12, week 24
Impact of the pathway on caregiver burden
Time frame: week 12
Impact of the pathway on healthcare professionals participating in the pathway to screen vulnerability and prevent treatment
Time frame: week 12
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jan 2026.
- Derived from this study: PubMed 40504480Franzoi MA, Santolaya C, Martin E, Fasse L, Rouby P, Minot-This MS, Di Meglio A, Vaz-Luis I. "Let's talk about risk": co-designing a pathway to assess, communicate and act on individual risk of long-term toxicities after breast cancer. J Cancer Surviv. 2025 Jun 12. doi: 10.1007/s11764-025-01826-0. Online ahead of print.
- Derived from this study: PubMed 39186774Franzoi MA, Pages A, Papageorgiou L, Di Meglio A, Laparra A, Martin E, Barbier A, Renvoise N, Arvis J, Scotte F, Vaz-Luis I. Evaluating the Implementation of Integrated Proactive Supportive Care Pathways in Oncology: Master Protocol for a Cohort Study. JMIR Res Protoc. 2024 Aug 26;13:e52841. doi: 10.2196/52841.
Related trials for Any Cancer
RecruitingPhase 2
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
Rectal Adenocarcinoma, Clinical Stage: Stage II (T3-4, N-)
Active, not recruitingPhase 2
Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)
Malignant Solid Neoplasm
Active, not recruitingPhase 3
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Breast Cancer
Active, not recruitingPhase 3
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
ER-Positive HER2-Negative Breast Cancer
Not yet recruitingPhase 2
Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse Events
Any Advanced Solid Tumors
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Maria Alice BORINELLI-FRANZOI contact
Ines VAZ LUIS principal investigator
Gustave Roussy, Cancer Campus, Grand Paris
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Any Cancer, run by Gustave Roussy, Cancer Campus, Grand Paris at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 16 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Maria Alice BORINELLI-FRANZOI (+33 (0)1 42 11 42 11, Mariaalice.BORINELLI-FRANZOI@gustaveroussy.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Patient distress (time frame: over a 12-week period after the integrated supportive care needs assessment.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06479057, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jan 2026.